2. Search Result
Search Result
Results for "

FAO

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50202A
    Etomoxir sodium salt
    Maximum Cited Publications
    68 Publications Verification

    (R)-(+)-Etomoxir sodium salt

    		 Apoptosis Metabolic Disease Cancer
    Etomoxir((R)-(+)-Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig .
    Etomoxir sodium salt
  • HY-50202
    Etomoxir
    Maximum Cited Publications
    68 Publications Verification

    (R)-(+)-Etomoxir

    		 Apoptosis Metabolic Disease Cancer
    Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
    Etomoxir
  • HY-B0280
    Ranolazine
    3 Publications Verification

    CVT 303; RS 43285-003

    		 Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine
  • HY-161027
    DHP-B

    		Apoptosis Cancer
    DHP-B possesses anti-cancer activity and induces apoptosis. DHP-B covalently binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 interaction, leading to increased mitochondrial permeability and reduced oxygen consumption and energy metabolism in CRC cells. DHP-B can be isolated from the plant Peperomia dindygulensis .
    DHP-B
  • HY-W420033
    (S)-(+)-Etomoxir

    		Others Others
    (S)-(+)-Etomoxir is the S enantiomer of Etomoxir (HY-50202). Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig .
    (S)-(+)-Etomoxir
  • HY-B0280S2
    Ranolazine-d3

    		Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
    Ranolazine-d3
  • HY-B0280S1
    Ranolazine-d8

    		Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
    Ranolazine-d8
  • HY-B0280S
    Ranolazine-d5

    CVT 303-d5; RS 43285-003-d5

    		 Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
    Ranolazine-d5
  • HY-B0280R
    Ranolazine (Standard)

    		Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine (Standard)
  • HY-126876
    GL-V9

    		Apoptosis AMPK Reactive Oxygen Species Cancer
    GL-V9 inhibits proliferation of HepG2 cell (IC50 is 35.2 μM) through induction of apoptosis and cell cycle arrest at G2/M phase. GL-V9 regulates mitochondrial membrane potential and increases the production of intracellular reactive oxygen species. GL-V9 inhibits the pentose phosphate pathway (PPP), enhances fatty acid oxidation (FAO) through activation of AMPK, and thus inhibits the metastasis of cancer cells. GL-V9 exhibits antitumor efficacy in mouse model .
    GL-V9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: